Plain-English translation of NCT03243175 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
After a brain bleed, people with irregular heart rhythm (atrial fibrillation) face a difficult choice: taking blood thinners to prevent stroke increases the risk of another bleed. This trial compares three strategies to help doctors and patients decide the safest path forward: taking a blood thinner called apixaban, having a small device placed to close part of the heart, or avoiding blood thinners altogether while being monitored carefully.
Doctors and patients struggle with a difficult trade-off after brain bleeding: blood thinners prevent stroke but may cause more bleeding, while avoiding them raises stroke risk. This trial exists to find which approach offers the best balance of safety and protection for this group of patients.
You likely qualify if…
You likely don't qualify if…
If you join, you will be randomly assigned to one of three groups: taking a daily blood thinner medication, having a heart device procedure, or avoiding blood thinners while being closely monitored. You will visit the study center at regular intervals over 24 months (about 2 years) so doctors can check your progress, monitor for any strokes or bleeding events, and track your overall health. The study team will carefully watch for both the benefits and risks of your assigned strategy.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
France